<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01089023</url>
  </required_header>
  <id_info>
    <org_study_id>ML22440</org_study_id>
    <nct_id>NCT01089023</nct_id>
  </id_info>
  <brief_title>A Study of Tocilizumab as Monotherapy or in Combination With DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis</brief_title>
  <official_title>Multicenter, Open-Label Study to Evaluate the Safety, Tolerability and the Effect on Disease Activity of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs Who Have an Inadequate Response to Current Non-biologic DMARD and/or Anti- TNF Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This open-label single-arm study will evaluate the safety, tolerability and efficacy of
      tocilizumab [RoActemra/Actemra] in patients with moderate to severe rheumatoid arthritis who
      experience an inadequate clinical response to a stable dose of non-biologic disease modifying
      anti-rheumatic drugs (DMARD) or anti-tumor necrosis factors (TNFs). RoActemra/Actemra will be
      administered as a monotherapy or in combination with DMARDs. RoActemra/Actemra will be
      administered as intravenous infusion at a dose of 8 mg/kg every 4 weeks for a total of 6
      infusions. The anticipated time on study treatment is 24 weeks. The target sample size is
      50-150 patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Reporting Any Adverse Event - Overall Summary of Events</measure>
    <time_frame>Baseline and Weeks 2, 4, 8, 12, 16, 20, and 24</time_frame>
    <description>Percentage of participants with a serious adverse event (SAE), who died, with an adverse event (AE), or study drug related AE during the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants by Disease Activity Score Based on 28-Joint Count (DAS28) Category</measure>
    <time_frame>Baseline and Weeks 4, 8, 12, 16, 20, and 24</time_frame>
    <description>DAS28 was calculated from the number of swollen joints and tender joints using the 28-joint count, the erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hr]) and global health assessment (participant rated global assessment of disease activity using 10-mm Visual analog scale - VAS); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity. A DAS28 score of greater than (&gt;)5.1 indicated high disease activity, a score of &gt;3.2 but less than or equal to (≤)5.1 indicated moderate disease activity, a score of greater than or equal to (≥)2.6 but ≤3.2 indicated low disease activity, and a score of less than &lt;2.6 indicated disease remission. Week 24 is the Follow-Up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a Clinically Meaningful Improvement as Measured by DAS28</measure>
    <time_frame>Weeks 4, 8, 12, 16, 20, and 24</time_frame>
    <description>DAS28 was calculated from the number of swollen joints and tender joints using the 28-joint count, the ESR (mm/hr) and global health assessment (participant rated global assessment of disease activity using 10-mm VAS); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity. Participants achieved a clinically meaningful improvement in DAS28 if there was a reduction of at least 1.2 units from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to DAS28 Response by DAS28 Category</measure>
    <time_frame>Weeks 4, 8, 12, 16, 20, and 24</time_frame>
    <description>Time to response is the number of days from date of first infusion to date of event. DAS28 response was defined as achievement of Low Disease Activity (DAS28 ≥2.6 to ≤3.2), Remission (DAS28 &lt;2.6), or Clinically Meaningful Improvement (change of &gt;1.2 from baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) of at Least 0.22 Units</measure>
    <time_frame>Weeks 4, 8, 12, 16, 20, and 24</time_frame>
    <description>HAQ includes 20 questions concerning participant's activities of daily life, grouped in 8 scales of 2 to 3 questions for each activity. To respond to each question, a four-level response (score of 0 to 3 points), with higher scores showing larger functional limitations, was chosen. Scoring was as follows with respect to performance of participant's everyday activities: 0=without difficulties; 1= with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all. Minimum score was 0, maximum score was 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Improvement in Physical Function by HAQ-DI Category</measure>
    <time_frame>Baseline, Weeks 4, 8, 12, 16, 20, and 24</time_frame>
    <description>Physical function scoring was as follows with respect to performance of participant's everyday activities: 0=without difficulties; 1= with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all. Minimum score was 0, maximum score was 3. The HAQ-DI score at every visit was categorized into none to mild disability (HAQ-DI &lt;1), moderate disability (1≤ HAQ-DI &lt;2) and severe disability (HAQ-DI ≥2). The percentages of the participants falling in each of these categories with respect to the visits were determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HAQ-DI Score by Visit</measure>
    <time_frame>Baseline and Weeks 4, 8, 12, 16, 20, and 24</time_frame>
    <description>HAQ includes 20 questions concerning participant's activities of daily life, grouped in 8 scales of 2 to 3 questions for each activity. To respond to each question, a four-level response (score of 0 to 3 points), with higher scores showing larger functional limitations, was chosen. Scoring was as follows with respect to performance of participant's everyday activities: 0=without difficulties; 1= with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all. Minimum score was 0, maximum score was 3..</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-Reactive Protein (CRP) Values by Study Visit</measure>
    <time_frame>Baseline and Weeks 4, 8, 12, 16, 20, and 24</time_frame>
    <description>CRP is an acute phase inflammatory marker. The serum concentration of CRP is measured in milligrams per liter (mg/L). A reduction in the level is considered an improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythrocyte Sedimentation Rate</measure>
    <time_frame>Baseline and Weeks 4, 8, 12, 16, 20, and 24</time_frame>
    <description>ESR (measured in mm/hr) is an inflammation marker used to determine acute phase response.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">95</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tocilizumab [RoActemra/Actemra]</intervention_name>
    <description>8 mg/kg iv infusion, every 4 weeks for a total of 6 infusions</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult patients, &gt;/=18 years of age

          -  moderate to severe rheumatoid arthritis (DAS28 &gt;3.2) of 6 months duration

          -  inadequate clinical response to non-biologic DMARDs or anti-TNF

          -  bodyweight &lt;/=150 kg

        Exclusion Criteria:

          -  rheumatic autoimmune disease or inflammatory joint disease other than RA

          -  major surgery within 8 weeks prior to screening or planned major surgery within 6
             months following screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Manama</city>
        <zip>12</zip>
        <country>Bahrain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riffa</city>
        <zip>28743</zip>
        <country>Bahrain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Isfahan</city>
        <zip>8174675731</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tehran</city>
        <zip>1333631151</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tehran</city>
        <zip>14114</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Safat</city>
        <zip>13041</zip>
        <country>Kuwait</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Doha</city>
        <zip>3050</zip>
        <country>Qatar</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Abu Dhabi</city>
        <zip>51900</zip>
        <country>United Arab Emirates</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Abu Dhabi</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bahrain</country>
    <country>Iran, Islamic Republic of</country>
    <country>Kuwait</country>
    <country>Qatar</country>
    <country>United Arab Emirates</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2010</study_first_submitted>
  <study_first_submitted_qc>March 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2010</study_first_posted>
  <results_first_submitted>June 23, 2014</results_first_submitted>
  <results_first_submitted_qc>June 23, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 22, 2014</results_first_posted>
  <last_update_submitted>June 23, 2014</last_update_submitted>
  <last_update_submitted_qc>June 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tocilizumab 8 Milligrams Per Kilogram (mg/kg)</title>
          <description>Participants received tocilizumab 8 mg/kg intravenous (IV) infusion, once every 4 weeks for a total of 6 infusions.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All the participants who were administered treatment at each visit were considered during the analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>Tocilizumab 8 mg/kg</title>
          <description>Participants received tocilizumab 8 mg/kg IV infusion, once every 4 weeks for a total of 6 infusions.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="95"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.89" spread="13.677"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Reporting Any Adverse Event - Overall Summary of Events</title>
        <description>Percentage of participants with a serious adverse event (SAE), who died, with an adverse event (AE), or study drug related AE during the study.</description>
        <time_frame>Baseline and Weeks 2, 4, 8, 12, 16, 20, and 24</time_frame>
        <population>All the participants who were administered treatment at each visit were considered during the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab 8 mg/kg</title>
            <description>Participants received tocilizumab 8 mg/kg IV infusion, once every 4 weeks for a total of 6 infusions.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Any Adverse Event - Overall Summary of Events</title>
          <description>Percentage of participants with a serious adverse event (SAE), who died, with an adverse event (AE), or study drug related AE during the study.</description>
          <population>All the participants who were administered treatment at each visit were considered during the analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With an SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Who Died</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With any drug-related AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants by Disease Activity Score Based on 28-Joint Count (DAS28) Category</title>
        <description>DAS28 was calculated from the number of swollen joints and tender joints using the 28-joint count, the erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hr]) and global health assessment (participant rated global assessment of disease activity using 10-mm Visual analog scale - VAS); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity. A DAS28 score of greater than (&gt;)5.1 indicated high disease activity, a score of &gt;3.2 but less than or equal to (≤)5.1 indicated moderate disease activity, a score of greater than or equal to (≥)2.6 but ≤3.2 indicated low disease activity, and a score of less than &lt;2.6 indicated disease remission. Week 24 is the Follow-Up visit.</description>
        <time_frame>Baseline and Weeks 4, 8, 12, 16, 20, and 24</time_frame>
        <population>All the participants who were administered treatment at each visit were considered during the analysis.
n (number) at Week 24 equals (=) number of participants in that visit; n at Other Visits = number of participants with treatment administered</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab 8 mg/kg</title>
            <description>Participants received tocilizumab 8 mg/kg IV infusion, once every 4 weeks for a total of 6 infusions.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants by Disease Activity Score Based on 28-Joint Count (DAS28) Category</title>
          <description>DAS28 was calculated from the number of swollen joints and tender joints using the 28-joint count, the erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hr]) and global health assessment (participant rated global assessment of disease activity using 10-mm Visual analog scale - VAS); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity. A DAS28 score of greater than (&gt;)5.1 indicated high disease activity, a score of &gt;3.2 but less than or equal to (≤)5.1 indicated moderate disease activity, a score of greater than or equal to (≥)2.6 but ≤3.2 indicated low disease activity, and a score of less than &lt;2.6 indicated disease remission. Week 24 is the Follow-Up visit.</description>
          <population>All the participants who were administered treatment at each visit were considered during the analysis.
n (number) at Week 24 equals (=) number of participants in that visit; n at Other Visits = number of participants with treatment administered</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>High Disease Activity, Baseline (n=95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Disease Activity, Week 4 (n=93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Disease Activity, Week 8 (n=91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Disease Activity, Week 12 (n=89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Disease Activity, Week 16 (n=89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Disease Activity, Week 20 (n=88)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Disease Activity, Week 24 (n=95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Disease Activity, Baseline (n=95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Disease Activity, Week 4 (n=93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Disease Activity, Week 8 (n=91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Disease Activity, Week 12 (n=89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Disease Activity, Week 16 (n=89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Disease Activity, Week 20 (n=88)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Disease Activity, Week 24 (n=95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Disease Activity, Baseline (n=95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Disease Activity, Week 4 (n=93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Disease Activity, Week 8 (n=91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Disease Activity, Week 12 (n=89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Disease Activity, Week 16 (n=89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Disease Activity Week 20 (n=88)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Disease Activity Week 24 (n=95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission Baseline (n=95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission Week 4 (n=93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission Week 8 (n=91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission Week 12 (n=89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission Week 16 (n=89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission Week 20 (n=88)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission Week 24 (n=95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a Clinically Meaningful Improvement as Measured by DAS28</title>
        <description>DAS28 was calculated from the number of swollen joints and tender joints using the 28-joint count, the ESR (mm/hr) and global health assessment (participant rated global assessment of disease activity using 10-mm VAS); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity. Participants achieved a clinically meaningful improvement in DAS28 if there was a reduction of at least 1.2 units from baseline.</description>
        <time_frame>Weeks 4, 8, 12, 16, 20, and 24</time_frame>
        <population>All the participants who were administered treatment at each visit were considered during the analysis.
n at Week 24 = number of participants in that visit; n at Other Visits = number of participants with treatment administered</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab 8 mg/kg</title>
            <description>Participants received tocilizumab 8 mg/kg IV infusion, once every 4 weeks for a total of 6 infusions.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a Clinically Meaningful Improvement as Measured by DAS28</title>
          <description>DAS28 was calculated from the number of swollen joints and tender joints using the 28-joint count, the ESR (mm/hr) and global health assessment (participant rated global assessment of disease activity using 10-mm VAS); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity. Participants achieved a clinically meaningful improvement in DAS28 if there was a reduction of at least 1.2 units from baseline.</description>
          <population>All the participants who were administered treatment at each visit were considered during the analysis.
n at Week 24 = number of participants in that visit; n at Other Visits = number of participants with treatment administered</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (n=93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=88)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to DAS28 Response by DAS28 Category</title>
        <description>Time to response is the number of days from date of first infusion to date of event. DAS28 response was defined as achievement of Low Disease Activity (DAS28 ≥2.6 to ≤3.2), Remission (DAS28 &lt;2.6), or Clinically Meaningful Improvement (change of &gt;1.2 from baseline).</description>
        <time_frame>Weeks 4, 8, 12, 16, 20, and 24</time_frame>
        <population>All the participants who were administered treatment at each visit were considered during the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab 8 mg/kg</title>
            <description>Participants received tocilizumab 8 mg/kg IV infusion, once every 4 weeks for a total of 6 infusions.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to DAS28 Response by DAS28 Category</title>
          <description>Time to response is the number of days from date of first infusion to date of event. DAS28 response was defined as achievement of Low Disease Activity (DAS28 ≥2.6 to ≤3.2), Remission (DAS28 &lt;2.6), or Clinically Meaningful Improvement (change of &gt;1.2 from baseline).</description>
          <population>All the participants who were administered treatment at each visit were considered during the analysis.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clinically meaningful Improvement in DAS28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.430" spread="2.355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low disease activity (≥2.6 to ≤3.2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.261" spread="5.587"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission (&lt;2.6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.945" spread="4.395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) of at Least 0.22 Units</title>
        <description>HAQ includes 20 questions concerning participant’s activities of daily life, grouped in 8 scales of 2 to 3 questions for each activity. To respond to each question, a four-level response (score of 0 to 3 points), with higher scores showing larger functional limitations, was chosen. Scoring was as follows with respect to performance of participant’s everyday activities: 0=without difficulties; 1= with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all. Minimum score was 0, maximum score was 3.</description>
        <time_frame>Weeks 4, 8, 12, 16, 20, and 24</time_frame>
        <population>All the participants who were administered treatment at each visit were considered during the analysis.
n at Week 24 = number of participants in that visit; n at Other Visits = number of participants with treatment administered</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab 8 mg/kg</title>
            <description>Participants received tocilizumab 8 mg/kg IV infusion, once every 4 weeks for a total of 6 infusions.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) of at Least 0.22 Units</title>
          <description>HAQ includes 20 questions concerning participant’s activities of daily life, grouped in 8 scales of 2 to 3 questions for each activity. To respond to each question, a four-level response (score of 0 to 3 points), with higher scores showing larger functional limitations, was chosen. Scoring was as follows with respect to performance of participant’s everyday activities: 0=without difficulties; 1= with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all. Minimum score was 0, maximum score was 3.</description>
          <population>All the participants who were administered treatment at each visit were considered during the analysis.
n at Week 24 = number of participants in that visit; n at Other Visits = number of participants with treatment administered</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (n=93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=88)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Improvement in Physical Function by HAQ-DI Category</title>
        <description>Physical function scoring was as follows with respect to performance of participant’s everyday activities: 0=without difficulties; 1= with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all. Minimum score was 0, maximum score was 3. The HAQ-DI score at every visit was categorized into none to mild disability (HAQ-DI &lt;1), moderate disability (1≤ HAQ-DI &lt;2) and severe disability (HAQ-DI ≥2). The percentages of the participants falling in each of these categories with respect to the visits were determined.</description>
        <time_frame>Baseline, Weeks 4, 8, 12, 16, 20, and 24</time_frame>
        <population>All the participants who were administered treatment at each visit were considered during the analysis.
n at Week 24 = number of participants in that visit; n at Other Visits = number of participants with treatment administered</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab 8 mg/kg</title>
            <description>Participants received tocilizumab 8 mg/kg IV infusion, once every 4 weeks for a total of 6 infusions.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Improvement in Physical Function by HAQ-DI Category</title>
          <description>Physical function scoring was as follows with respect to performance of participant’s everyday activities: 0=without difficulties; 1= with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all. Minimum score was 0, maximum score was 3. The HAQ-DI score at every visit was categorized into none to mild disability (HAQ-DI &lt;1), moderate disability (1≤ HAQ-DI &lt;2) and severe disability (HAQ-DI ≥2). The percentages of the participants falling in each of these categories with respect to the visits were determined.</description>
          <population>All the participants who were administered treatment at each visit were considered during the analysis.
n at Week 24 = number of participants in that visit; n at Other Visits = number of participants with treatment administered</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAQ-DI &lt;1 Baseline (n=95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI &lt;1 Week 4 (n=93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI &lt;1 Week 8 (n=91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI &lt;1 Week 12 (n=89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI &lt;1 Week 16 (n=89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI &lt;1 Week 20 (n=88)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI &lt;1 Week 24 (n=95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≤1 HAQ-DI &lt;2 Baseline (n=95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≤1 HAQ-DI &lt;2 Week 4 (n=93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≤1 HAQ-DI &lt;2 Week 8 (n=91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≤1 HAQ-DI &lt;2 Week 12 (n=89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≤1 HAQ-DI &lt;2 Week 16 (n=89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≤1 HAQ-DI &lt;2 Week 20 (n=88)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≤1 HAQ-DI &lt;2 Week 24 (n=95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI ≥2 Baseline (n=95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI ≥2 Week 4 (n=93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI ≥2 Week 8 (n=91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI ≥2 Week 12 (n=89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI ≥2 Week 16 (n=89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI ≥2 Week 20 (n=88)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI ≥2 Week 24 (n=95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HAQ-DI Score by Visit</title>
        <description>HAQ includes 20 questions concerning participant’s activities of daily life, grouped in 8 scales of 2 to 3 questions for each activity. To respond to each question, a four-level response (score of 0 to 3 points), with higher scores showing larger functional limitations, was chosen. Scoring was as follows with respect to performance of participant’s everyday activities: 0=without difficulties; 1= with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all. Minimum score was 0, maximum score was 3..</description>
        <time_frame>Baseline and Weeks 4, 8, 12, 16, 20, and 24</time_frame>
        <population>All the participants who were administered treatment at each visit were considered during the analysis.
n at Week 24 = number of participants in that visit; n at Other Visits = number of participants with treatment administered</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab 8 mg/kg</title>
            <description>Participants received tocilizumab 8 mg/kg IV infusion, once every 4 weeks for a total of 6 infusions.</description>
          </group>
        </group_list>
        <measure>
          <title>HAQ-DI Score by Visit</title>
          <description>HAQ includes 20 questions concerning participant’s activities of daily life, grouped in 8 scales of 2 to 3 questions for each activity. To respond to each question, a four-level response (score of 0 to 3 points), with higher scores showing larger functional limitations, was chosen. Scoring was as follows with respect to performance of participant’s everyday activities: 0=without difficulties; 1= with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all. Minimum score was 0, maximum score was 3..</description>
          <population>All the participants who were administered treatment at each visit were considered during the analysis.
n at Week 24 = number of participants in that visit; n at Other Visits = number of participants with treatment administered</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.570" spread="0.6157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.185" spread="0.7092"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.972" spread="0.6236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.805" spread="0.5634"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.680" spread="0.4804"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=88)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.576" spread="0.4812"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.551" spread="0.5139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>C-Reactive Protein (CRP) Values by Study Visit</title>
        <description>CRP is an acute phase inflammatory marker. The serum concentration of CRP is measured in milligrams per liter (mg/L). A reduction in the level is considered an improvement.</description>
        <time_frame>Baseline and Weeks 4, 8, 12, 16, 20, and 24</time_frame>
        <population>All the participants who were administered treatment at each visit were considered during the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab 8 mg/kg</title>
            <description>Participants received tocilizumab 8 mg/kg IV infusion, once every 4 weeks for a total of 6 infusions.</description>
          </group>
        </group_list>
        <measure>
          <title>C-Reactive Protein (CRP) Values by Study Visit</title>
          <description>CRP is an acute phase inflammatory marker. The serum concentration of CRP is measured in milligrams per liter (mg/L). A reduction in the level is considered an improvement.</description>
          <population>All the participants who were administered treatment at each visit were considered during the analysis.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.90" spread="34.406"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.49" spread="29.074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.84" spread="23.116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.32" spread="10.614"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.18" spread="8.105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.62" spread="8.618"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.59" spread="21.702"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>p-value measures the significance between each visit using analysis of variance</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Erythrocyte Sedimentation Rate</title>
        <description>ESR (measured in mm/hr) is an inflammation marker used to determine acute phase response.</description>
        <time_frame>Baseline and Weeks 4, 8, 12, 16, 20, and 24</time_frame>
        <population>All the participants who were administered treatment at each visit were considered during the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab 8 mg/kg</title>
            <description>Participants received tocilizumab 8 mg/kg IV infusion, once every 4 weeks for a total of 6 infusions.</description>
          </group>
        </group_list>
        <measure>
          <title>Erythrocyte Sedimentation Rate</title>
          <description>ESR (measured in mm/hr) is an inflammation marker used to determine acute phase response.</description>
          <population>All the participants who were administered treatment at each visit were considered during the analysis.</population>
          <units>mm/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.27" spread="29.227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.61" spread="14.118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.66" spread="11.554"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.52" spread="10.361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.83" spread="6.386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.60" spread="8.576"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.17" spread="12.311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>p-value measures the significance between each visit using analysis of variance</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events data were collected from the date of first dose of study drug administration to the end of study at Week 24.</time_frame>
      <desc>Nonserious adverse events presented in this record include all adverse events reported during the study, not just nonserious events. Note that available data included a summary of events by system organ class only, no data provided by preferred term.</desc>
      <group_list>
        <group group_id="E1">
          <title>Tocilizumab</title>
          <description>Participants received tocilizumab 8 mg/kg iv infusion, every 4 weeks for a total of 6 infusions.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection and infestation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and nutrition disorders</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and lymphatic system disorders</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditions</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning, and procedural complications</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and nutrition disorders</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorders</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic, and mediastinal disorders</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but after the first publication or presentation that involves the overall study. Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Nonserious adverse events presented in this record include all adverse events reported during the study, not just nonserious events.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffmann- LaRoche</organization>
      <phone>800-821-8590</phone>
      <email>genentech@druginfo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

